Can-Fite BioPharma Ltd. (CANF) 股票分析

公司概述

Can-Fite BioPharma Ltd. operates as a clinical-stage biopharmaceutical company dedicated to the development of orally bioavailable small molecule therapeutic products aimed at treating cancer, liver inflammatory diseases, and erectile dysfunction within the Israeli market. The firm functions within the broader healthcare sector, specifically the biotechnology industry, which implies a focus on high-risk, high-reward research and development activities rather than established commercial manufacturing. As of the latest available data, the company possesses a market capitalization of $6.88M, generates annual revenue of $405,000, and maintains an operational workforce of 5 employees. These specific valuation and revenue figures indicate that Can-Fite BioPharma is a micro-cap entity with a highly specialized niche, suggesting that its market position is defined by early-stage asset value rather than current commercial scale or broad consumer reach.

财务健康

The company reported a revenue of $405,000 for the trailing twelve months, while simultaneously recording a net income of $-9,828,000 and an EBITDA of $-9,926,000, highlighting a significant structural gap where operational costs vastly exceed top-line generation. This disparity reveals a cost structure dominated by heavy research and development expenditures or other operational burn typical of clinical-stage biotech firms, resulting in a substantial loss relative to current sales volume. The free cash flow stands at $-4,985,750, which indicates that the company is consuming its cash reserves to fund operations and development programs rather than generating internal liquidity. Despite the negative cash flow, the balance sheet includes $8.54M in cash against a relatively minor debt obligation of $71,000, creating a substantial cash buffer relative to liabilities. The debt-to-equity ratio is recorded at 1.27, a metric that requires careful interpretation given the context of a pre-revenue or low-revenue biotechnology business model. Short-term liquidity appears robust, evidenced by a current ratio of 3.46, which suggests the company holds sufficient current assets to cover its short-term obligations multiple times over. However, the return on equity is -178.2% and the return on assets is -66.7%, metrics that reveal management has not yet achieved profitability and that the capital base is currently being eroded by operational expenses rather than generating returns for shareholders.

估值评估

The trailing twelve-month P/E ratio is listed as N/A due to the negative net income, while the forward P/E is reported as -4.01, reflecting the expectation of continued losses or the challenges in applying traditional earnings-based valuation to a loss-making biotech firm. The price-to-book ratio stands at 0.69, indicating that the market is currently valuing the company at a discount to its net asset value, which is common for speculative biotechnology stocks lacking commercialized products. Alternative valuation metrics such as the price-to-sales ratio of 16.98 and the EV/EBITDA of -0.41 provide a different perspective, suggesting that investors are pricing the stock based on pipeline potential and asset value rather than current profitability. The stock has experienced significant volatility, with a 52-week high of $36.40 and a 52-week low of $2.93, illustrating a wide trading range typical of small-cap biopharmaceutical companies subject to clinical trial outcomes. Although the exact current trading price is not provided in the source data, the historical range demonstrates that the stock has experienced a dramatic decline from its peak, potentially trading well below the 52-week high depending on recent market movements. The beta value is -0.10, a unique and rare statistic that suggests the stock's price movements have historically moved in the opposite direction of the broader market or displayed negligible correlation, deviating from standard volatility expectations.

Growth & Income

Revenue growth year-over-year is recorded at -43.3%, while earnings growth is N/A due to the absence of positive earnings in the prior period, indicating a contraction in commercial activity or a decline in revenue streams. The negative revenue growth implies that the company is in a phase where commercial sales may be insufficient to offset the costs of ongoing clinical development or that previous revenue peaks have been exceeded by subsequent declines. Since the company does not distribute dividends, the dividend yield is N/A and the payout ratio is 0.0%, meaning the firm retains all of its limited cash flow to reinvest into its drug development pipeline rather than returning capital to shareholders. Consequently, the overall growth and income profile is characterized by a lack of current income generation and negative growth metrics, placing the company squarely in the speculative growth category where value is derived entirely from future product approvals rather than present-day financial performance.